Aileron Therapeutics Inc. is a biotechnology company that focuses on the development and commercialization of novel chemotherapies for the treatment of cancer. The company’s lead product candidate is ALRN-6924, a first-in-class MDM2/MDMX dual inhibitor that is being evaluated in clinical trials for the treatment of a variety of solid tumors. Aileron Therapeutics is driven by a mission to improve the lives of cancer patients through innovative and targeted therapies.
Notification